New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
05:17 EDTKPTIKaryopharm announces first combination data of Selinexor Phase 1 trial
Karyopharm Therapeutics announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm's lead selective inhibitor of nuclear export, or SINE, Selinexor, in combination with "low-dose" dexamethasone. Among eight patients, the best responses were one stringent complete response, or sCR, three partial responses, or PRs, two minor responses, or MRs, one progressive disease and one non-evaluable. Accordingly, the clinical benefit response rate is 75% and the overall response rate. Adverse events in patients receiving single-agent Selinexor were generally low-grade, consistent with events observed in patients with other hematological malignancies and responsive to standard supportive care. Compared with Selinexor given alone, fewer adverse events in patients receiving Selinexor in combination with dexamethasone were reported, consistent with dexamethasone's reduction in Selinexor's main side effects of nausea, anorexia, and fatigue.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
10:04 EDTKPTIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:27 EDTKPTIKaryopharm initiates clinical study of Selinexor
Subscribe for More Information
07:26 EDTKPTIKaryopharm sees existing cash, cash equivalents to fund R&D into 2H17
Karyopharm expects to end 2014 with greater than $200M in cash and cash equivalents.
07:26 EDTKPTIKaryopharm reports Q3 EPS (61c), consensus (52c)
Subscribe for More Information
07:18 EDTKPTIKaryopharm upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use